Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells (original) (raw)

• Home

• Submit Manuscript

• My Account

• Authors:

  • Rajesh L. Thangapazham
  • Anu Puri
  • Shrikant Tele
  • Robert Blumenthal
  • Radha K. Maheshwari

• View Affiliations
  Affiliations: Center for Combat Casualty and Life Sustainment Research, Department of Pathology, Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD 20814, USA

• Published online on: May 1, 2008 https://doi.org/10.3892/ijo.32.5.1119

• Pages: 1119-1123

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

This article is mentioned in:

Abstract

We have initiated studies to enhance targeted delivery of an anticancer agent, curcumin, for prostate cancer treatment by incorporating this agent into the liposomes (nanodelivery vehicles primarily composed of phospholipids) coated with prostate membrane specific antigen specific antibodies. We prepared curcumin-loaded liposomes of various lipid compositions by sonication at an average size of 100-150 nm. Un-entrapped curcumin was removed by size exclusion chromatography. Data show that curcumin preferentially partitioned into liposomes prepared from dimyristoyl phosphatidyl choline (DMPC) and cholesterol among the various compositions tested. The anti-proliferative activity of liposomal curcumin was studied using two human prostate cancer cell lines (LNCaP and C4-2B) by a tetrazolium dye-based (MTT) assay. Treatment of cells with liposomal curcumin (5-10 µM) for 24-48 h at 37°C resulted in at least 70-80% inhibition of cellular proliferation without affecting their viability. On the other hand, free curcumin exhibited similar inhibition only at 10-fold higher doses (>50 µM). We also observed that LNCaP cells were relatively more sensitive to liposomal curcumin mediated block of cellular proliferation than C4-2B cells. We are currently developing liposome formulations with targeting ability to further improve the efficacy of curcumin in vivo.

Related Articles

• View Abstract
• Cite This Article
• Download Citation
• Create Citation Alert
• Remove Citation Alert
• Cited By
• on Spandidos Publications
• on Google Scholar
• on Pub Med
• © Get Permissions
• Impact Factor: 4.5
• Ranked Oncology
  (total number of cites)
• CiteScore: 9.6
• CiteScore Rank: Q1: #66/404 Oncology
• Source Normalized Impact per Paper (SNIP): 0.88
• SCImago Journal Rank (SJR): 1.099

Copy and paste a formatted citation

Spandidos Publications style

Thangapazham RL, Puri A, Tele S, Blumenthal R and Maheshwari RK: Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 32: 1119-1123, 2008.

APA

Thangapazham, R.L., Puri, A., Tele, S., Blumenthal, R., & Maheshwari, R.K. (2008). Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. International Journal of Oncology, 32, 1119-1123. https://doi.org/10.3892/ijo.32.5.1119

MLA

Thangapazham, R. L., Puri, A., Tele, S., Blumenthal, R., Maheshwari, R. K."Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells". International Journal of Oncology 32.5 (2008): 1119-1123.

Chicago

Thangapazham, R. L., Puri, A., Tele, S., Blumenthal, R., Maheshwari, R. K."Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells". International Journal of Oncology 32, no. 5 (2008): 1119-1123. https://doi.org/10.3892/ijo.32.5.1119